Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Bonus Content from MarketBeat Media The Often-Missed Corner of Healthcare That Wall Street Is LovingAuthor: Nathan Reiff. Article Posted: 3/29/2026. 
Key Points - Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to see some of the wildest spikes and drops across the market. Investors who want exposure to the healthcare space but are wary of that volatility may adopt a "picks and shovels" approach, focusing on companies that supply essential equipment and services rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked by healthcare investors, even though several companies in this subindustry rank among the largest in the space. Given the external factors that could affect healthcare in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab equipment names may be especially attractive. Below are some major players worth a closer look. A Recent Dip Masks Thermo Fisher's Long-Term Strengths In March 1968, central banks ran out of gold and London markets shut down - miners surged 2,329%. In 1980, a COMEX delivery wall sent silver miners like Silverado up 3,989%. Today, registered gold inventory is down 25% while prices sit at record highs. Dylan Jovine of Behind the Markets says May 29, 2026 is the next inflection point - and he has identified one stock sitting on more gold than France and Italy combined. See the historical pattern and Jovine's top pick before May 29th A $182 billion life sciences solutions, diagnostics, and analytical instruments company, Thermo Fisher Scientific (NYSE: TMO) has had a rough start to 2026, with shares down more than 15% year-to-date (YTD) after the stock entered TradeSmith's "red zone" for financial health. A sizeable portion of that recent weakness appears linked to tariffs and foreign-exchange volatility, which together shaved over 100 basis points off margins in 2025. That said, there are several encouraging signs in Thermo Fisher's recent results. In Q4 2025, revenue rose 7% year over year to $12.2 billion, beating analyst forecasts by roughly $250 million. Adjusted earnings per share (EPS) also topped estimates at $6.57. Momentum may be supported by recent product launches, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor products. Even if 2026 guidance is cautious—revenue is projected to climb 4%–6%—improving EBITDA margins and strong underlying customer demand should provide a cushion. That may explain why analysts remain largely bullish: 17 of 19 rate the company a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains Modest Danaher Corp. (NYSE: DHR) shares are down nearly 20% YTD; like Thermo Fisher, the instruments, consumables, and reagents firm is facing headwinds. Although 2026 guidance calls for modest core revenue growth of 3% to 6% year over year, the latest quarter included both a top- and bottom-line beat and $5.3 billion in free cash flow for 2025. Two bright spots for 2026 are Danaher's bioprocessing business—expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand—and diagnostics. Diagnostics could benefit from recent FDA clearances, and equipment orders have begun to recover after a prolonged slump, which could further boost sales. Analysts are constructive on DHR, forecasting about 12.3% earnings growth and roughly 35% upside in the share price. Correspondingly, 19 of 22 analyst ratings are Buys. Agilent's Biocare Purchase Could Be a Catalyst Agilent Technologies (NYSE: A) appears to lag some peers: its latest earnings showed 4.4% year-over-year revenue growth and slight misses on revenue and earnings versus expectations. However, Agilent may have a growth driver in its recent acquisition of Biocare Medical, which strengthens its position in cancer diagnostics. Though Biocare cost nearly $1 billion, the deal should add recurring revenue in a growing area. Cancer diagnostics is likely a higher-margin business line than some of Agilent's existing operations, which could help lift operating margins (Agilent's operating margin was 24.6% last quarter). Despite a roughly 17% YTD decline, analysts see about 42% upside for Agilent shares. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 ratings at Buy or equivalent. | 
